Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06773403 · ClinicalTrials.gov registry record · Phase 4
Upadacitinib for Prurigo Nodularis
A Phase 4 study of Prurigo Nodularis, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06773403 is a Phase 4 study of Prurigo Nodularis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 25 participants, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06773403, a Phase 4 study of Prurigo Nodularis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Conditions Studied
Interventions
- DRUG Upadacitinib
Study Locations (1)
New Jersey
- Eczema Treatment Center of New Jersey - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2026-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06773403
The ClinicalTrials.gov registry entry for NCT06773403 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (89% lower). The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Upadacitinib is the first listed.
NCT06773403 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06773403 about?
NCT06773403 is a clinical study titled "Upadacitinib for Prurigo Nodularis". A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
What is the current status of trial NCT06773403?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2024-04-09. Estimated completion is 2026-01.
What conditions does trial NCT06773403 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06773403?
The interventions under investigation include: Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT06773403?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06773403 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
RECRUITING
-
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
ACTIVE NOT RECRUITING
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.